63% of deaths were reported in Eastern Europe, with the highest incidence in Romania (age-standardised rate of 28.6 per 100,000 women per year) and Lithuania (26.1 per 100,000) and the lowest in Malta (3.8 per 100,000) and Switzerland (3.6 per 100,000) (Bruni et al., April 8, 2015) . In Italy, about 2,918 new CC cases are diagnosed and about 1,016 deaths occur annually (Bruni et al., March 20, 2015) . The standardised incidence rate decreased from 13.7 per 100,000 women in 1980 to 6.2 per 100,000 in 2002 and to 4.2 per 100,000 in 2012; the standardised mortality rate declined from 7 per 100,000 women in 1980 to 1.6 per 100,000 in 2012 (Bruni et al., March 20, 2015; De Angelis et al., 2010; ISS, 2013) .
Organised screening programmes are generally considered the milestone in CC prevention: The long latent period between detectable preneoplastic lesions and the development of an invasive cancer (about 15-20 years) allows early diagnosis and treatment (Italian Ministry of Health, January 13, 2013; WHO, 2016) . In Italy, the implementation of organised cervical screening programmes within each region has been recommended since 1996 and included in the Ministry of Health's list of "Essential Health Interventions" since 2001 (Grazzini & Zappa, 2008) . Recommendations, largely based on European guidelines, include personal invitations to women aged 25-64 years for a Pap test every 3 years, a monitoring system and quality assurance for each phase of the programme. In 2012, the target population of these programmes amounted to 14, 497, 207 women, corresponding to 87.3% of Italian women aged 25-64 years; compliance with invitation was 40.8%, with a strong decreasing north-south trend; of all screened women, 2.4% were referred to colposcopy; the unadjusted detection rate of CIN2 or more severe histology was 3.4 per 1,000 screened women . As pointed out in the European quality assurance guidelines (von Karsa et al., 2015) , the most effective and appropriate way for reducing cervical cancer incidence and mortality is through implementation of population-based screening programmes. The implementation of HPV vaccination programmes will also reduce the burden of cervical cancer in the coming decades.
This study aimed to assess the cervical cancer burden and performance of screening programme over the last decade in Apulia, Italy, using routine data and predefined indicators.
| MATERIAL AND ME THODS

| Burden of cervical cancer
In Apulia, three data sources are routinely available for estimating the burden of cervical cancer: Crude and age-specific annual hospitalisation rates were calculated by dividing the number of discharges by the number of residents in Apulia (data from Italy's National Census Bureau estimate, years [2001] [2002] [2003] [2004] [2005] [2006] [2007] [2008] [2009] [2010] [2011] [2012] [2013] [2014] . In order to estimate incident CC cases, we performed hospitalisation data cleansing using pseudonymised personal ID number to identify readmissions; prevalent cases in the first years of the studied period were excluded from the analysis and crude and age- 
| Performance of cervical cancer screening
Using records collected by the regional screening information system, the performance of organised cervical screening programme during For each year, women invited during that year and screened within the first 4 months of the subsequent year were considered .
| Early impact of cervical cancer screening
To assess the early impact of cervical cancer screening implementation in Apulia, the burden of CC before and after the introduction of screening was estimated. Crude and age-specific hospitalisation rates in the "prescreening period," calculated as 
| Ethics
The study protocol was approved by the Institutional Review Board at the Apulian Regional Observatory for Epidemiology. The study was conducted according to the principles expressed in the Declaration of Helsinki. Informed consent was not obtained from participants because data from different sources were provided and analysed anonymously.
| RE SULTS
| Burden of cervical cancer
In Apulia region, the annual hospitalisation rate for CC decreased TA B L E 2 Hospitalisation rates and HRRs with 95% CIs (a), incidence rates and IRRs with 95% CIs (b), mortality rates and MRRs with 95% CIs for cervical cancer (c) and for other malignant neoplasms of uterus (d) in the "prescreening," the "screening start-up" and the "screening period. of cervical single biopsy (N = 1,879/year), followed by endocer- (Table 1) .
| Early impact of cervical cancer screening
Comparing the pre-and the screening period, hospitalisation rate Estimates from the Italian Network of Cancer Registries have
shown that the age-standardised incidence and mortality rates for cervical cancer were expected to decline markedly during the period 1980-2015, reaching the lowest figures (3.5 and 1.3 per 100,000, respectively) in 2015. The prevalence is also expected to decrease down to about 50 per 100,000 in 2015 (Rossi, Crocetti, Capocaccia, & Gatta, 2013) . We obtained similar trends in Apulia, with incidence and mortality figures for CC declining over the observed periods. In Apulia, a regional population-based cancer registry has been implemented in 2009 and only since 2012 the entire regional population has been covered by registration. By applying a statistical back-calculation approach to derive incidence and prevalence figures starting from mortality and relative survival data, a study from Galise et al. (2013) estimated that in Apulia the cervical cancer incidence and mortality rates were expected to decrease from 14.5 and 8.1 per 100,000 in 1980 to 3.5 and 1.6 in 2015 respectively.
In recent years, in Italy, many diagnostic and therapeutic procedures have been moved from the hospital to the ambulatory setting (Rosano et al., 2013) . So, a substantial decrease in hospitalisation rates for CC has been documented in Apulia in the period 2011-2014, especially among women >44 years ( Figure 1a , Table 2a ); accordingly, outpatient services prescriptions arose and more than 300 prescriptions for cauterisation and cryosurgery of the cervix were registered in the last years examined (Figure 2 ).
Organised cancer screening using evidence-based tests has considerable potential to improve the health of the target population, provided that programmes are implemented cost-effectively and with high quality (Veerus, Arbyn, Amati, & Paolo, 2010) . A recent study on the impact of organised screening in Italy showed that, in line with other international experiences, invasive cervical cancer incidence rates have been decreasing since its full activation, especially among women aged 45-74 years (Serraino et al., 2015) . A similar trend was observed also in Apulia since 2011. Compared to national data , the performance of the regional screening programme is still low, although the actual extension progressively increased up to 62% in 2014 and compliance with invitation was 32%/year. Puglia, anni 2011 Puglia, anni -2014 Puglia, anni , 2016 , showing that the organised screening improves coverage rates of cervical cancer prevention programmes.
Organised screening programmes using standard validated tests have been shown to be more effective than opportunistic or nonorganised screening, also because opportunistic screening tends to miss the women at the greatest risk (Anttila et al., 2004; Hakama, Coleman, Alexe, & Auvinen, 2008) ; its population-based approach ensures that screening also reaches the less fortunate who may be in greatest need of secondary prevention of cancer (Veerus et al., 2010) .
Our study has some limitations. Some of the presented data are shortly accurate for monitoring the trend of the disease, for example: mortality in Italy is dramatically misclassified; outpatient data could include procedures not related at all with CIN or invasive CC; screening data probably missing many histological results, etc. Despite these limitations, our findings provide estimates of cervical cancer burden and performance indicators of screening that can contribute to anticipate the future benefits of prevention programmes. Further planned studies will validate our data by applying more complex algorithms to make indicators more reliable (i.e., incidence-based mortality, record linkage between screening and hospital discharges).
Paradigms for cervical cancer screening are changing in highresource settings, including Italy, from cytology-based screening to adoption of molecular screening (von Karsa et al., 2015; Pimple, Mishra, & Shastri, 2016 (Williams, Carter, & Rychetnik, 2014) . By linking vaccination, cervical screening and HPV testing data, we will be able to estimate the decline in high-risk HPV vaccine types and nonvaccine types closely related to HPV16/18
(for cross-protection), herd immunity among nonvaccinated females and sustained effectiveness of the vaccines on virologic outcomes at the population level (Cameron et al., 2016) .
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